<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438658</url>
  </required_header>
  <id_info>
    <org_study_id>001-HMO-CTIL</org_study_id>
    <nct_id>NCT01438658</nct_id>
  </id_info>
  <brief_title>Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma</brief_title>
  <acronym>UM</acronym>
  <official_title>Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uveal melanoma is the most common primary intraocular tumor in adults. The local treatment is
      effective, but patients still die of metastatic disease. It has been shown that early
      diagnosis of a few isolated metastases can result in a clean surgical excision of the
      metastases and an extension of the expected survival from 7-12 months to over 10 years on
      some patients.

      Many serum biomarkers are employed in Oncology. It makes sense to try the relevant ones in
      the diagnosis of metastatic uveal melanoma.

      The investigators hypothesis is that a soluble serum biomarker level changes upon development
      of metastatic disease either by secretion by the tumor cells themselves or by their
      environment. Detection of changes in biomarker level may lead to the diagnosis of metastases
      before they can be detected by imaging modalities, thus allowing for early treatment of the
      metastases and a better chance of success.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2040</completion_date>
  <primary_completion_date type="Anticipated">December 2040</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significant increase in biomarker level that could be linked with detection of metastases by imaging</measure>
    <time_frame>up to 12 months before diagnosis of metastases</time_frame>
    <description>Serum will be taken on every clinic visit from the day of diagnosis and on. Change in biomarker level will be assessed from one visit to the previous one, and correlated with imaging information on detection of metastases.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>All</arm_group_label>
    <description>A cohort of all the patients.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sera from patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients diagnosed with uveal melanoma being treated at our center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of uveal melanoma

        Exclusion Criteria:

          -  refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahar Frenkel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahar Frenkel, MD, PhD</last_name>
    <phone>+972-2-6776579</phone>
    <email>shahar@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Specialized Ocular Oncology Service, Hadassah-Hebrew-University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahar Frenkel, MD, PhD</last_name>
      <phone>+972-2-6776579</phone>
      <email>shahar@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Shahar Frenkel, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, Pe'er J. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009 Aug;93(8):1042-6. doi: 10.1136/bjo.2008.153684. Epub 2009 May 7.</citation>
    <PMID>19429579</PMID>
  </reference>
  <reference>
    <citation>Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol. 2009 Nov;35(11):1192-7. doi: 10.1016/j.ejso.2009.02.016. Epub 2009 Mar 28.</citation>
    <PMID>19329272</PMID>
  </reference>
  <reference>
    <citation>Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 2009;223(4):239-43. doi: 10.1159/000206139. Epub 2009 Mar 6.</citation>
    <PMID>19270465</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>September 27, 2011</last_update_submitted>
  <last_update_submitted_qc>September 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveal melanoma</keyword>
  <keyword>metastatic uveal melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

